WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2015.
The Company operates in two primary markets - wearable therapeutic technology and point-of-care tests. It is preparing for the launch of its newest product, Quell™, an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The device is designed for users with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia and pain associated with osteoarthritis. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic intractable pain without a prescription. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy. Quell was unveiled at the January 2015 International Consumer Electronics Show where it was one of four finalists for “Best of CES” in the health & fitness category. The Company’s SENSUS® device offers similar therapy for chronic pain and requires a doctor’s prescription. It has been on the market for two years. The Company’s point-of-care neuropathy test, DPNCheck®, addresses an unmet medical need for accurate and cost-effective screening, diagnosing and monitoring of peripheral neuropathies such as diabetic peripheral neuropathy.
Help employers find you! Check out all the jobs and post your resume.
